20/20 invited to submit full application to create the C20/20 Centre for Ophthalmic Materials Development
Actively recruiting industry partners
Last summer we submitted a Letter of Intent (LOI) to Canada’s Networks of Centres of Excellence – Centres of Excellence for Commercialization of Research (NCE-CECR) program to create the C20/20 Centre for Ophthalmic Materials Development (C20/20). Our Letter of Intent was favourably reviewed and we are one of only eleven Canadian groups that have been invited to submit a full application.
The goal of the CECR program is to create internationally recognized centres of commercialization and research expertise in priority areas to deliver economic, social, health and environmental benefits to Canada. Funded centres are expected to become financially sustainable within a 7-10 year period.
C20/20 will be a globally unique hub for the commercialization of academia-derived ophthalmic materials:
- Ophthalmic drug delivery technologies. We will develop advanced materials to provide improved therapeutic release profiles for new and existing pharmaceuticals
- Advanced lens technologies. Our technologies allow us to control the biological response to lens materials, providing the potential to improve lens comfort and decrease complications
- Technologies for licensing to partners. The technologies above will be licensed to partners to enable them to increase their market share and to generate a stream of revenue for C20/20.
C20/20 will create value by:
- De-risking ocular drug delivery and lens technologies originating from Canadian universities and beyond, transforming them into solid investment opportunities.
- Developing advanced drug delivery systems. Pairing technology and therapy, we will develop drug delivery systems as products in their own right.
- Conducting contract research. C20/20 members will have access to our exceptional expertise and facilities. C20/20 will meet our members’ development needs with a full range of cost-effective contract research services.
C20/20 will have access to world-class facilities at McMaster University and the University of Waterloo:
- The recently created McMaster Better Vision Institute provides materials synthesis and characterization equipment and expertise as well as in vitro and vivo testing for novel materials
- The recently opened Biointerfaces Institute (BI) offers the latest technologies in high throughput material synthesis, characterization and screening, enabling rapid optimization of performance characteristics.
- The Centre for Contact Lens Research (CCLR) can initiate clinical trials for our most promising lens materials.
As the natural successor of the 20/20 Network, C20/20 will initially select the most promising technologies from 20/20 Network’s portfolio.
Diseases and Conditions Targeted
· Dry eye disease
· Retinal degenerative diseases
· Microbial keratitis
· Discomfort associated with contact lens use
· Hydrophilic silicones
· Thermoresponsive gels
· Mucoadhesive polymers
· (Bio)degradable hydrogels
· Mucoadhesive polymer to deliver glaucoma therapies
· Anti-inflammatory and MMP-inhibiting gel for treatment of dry eye disease
· Active coatings for contact lenses to improve comfort
) if you would like more information.
View the Entire 20/20 Network Newsletter for 2012-2013